Pharma Pulse: Regulatory Speed Records

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and let’s get into today’s headlines.

• Boehringer Ingelheim’s Hernexeos has just secured accelerated approval for first-line HER2-mutant lung cancer in a record 44 days. This marks another success for the Commissioner’s National Priority Voucher program, a pilot designed to slash review times for therapies that address critical unmet needs. With a 76% response rate in patients, this oral kinase inhibitor is setting a new benchmark for personalized oncology by sparing healthy cells while aggressively targeting the HER2 mutation.
• Meanwhile, CMS Administrator Mehmet Oz and Secretary RFK Jr. have unveiled the CRUSH initiative—a crackdown on healthcare fraud. The plan moves from "pay and chase" to proactive prevention, starting with a $260 million hold on Medicaid funds in Minnesota and a nationwide six-month freeze on new enrollments for medical equipment suppliers.

That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access and care delivery, visit pharmaceuticalcommerce.com.

Thanks for listening—until next time, stay well and stay informed.

You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.